A Study to Assess the Bioequivalence Between Brivaracetam Tablet & Dry

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The purpose of the study is to demonstrate the bioequivalence between the BRV tablet and BRV as dry syrup after a single oral dose in healthy Japanese male study participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Healthy Study Participants

Clinical Trial Details

NCT number	NCT05315947
Study type	Interventional
Source	UCB Pharma
Contact
Status	Completed
Phase	Phase 1
Start date	April 4, 2022
Completion date	May 13, 2022

See also
	Status	Clinical Trial	Phase
	Terminated	`NCT04136444` - A Pharmacokinetic Study of Padsevonil in Study Participants With Either Normal or Moderately Impaired Hepatic Function	Phase 1
	Terminated	`NCT04126343` - A Study to Test the Cardiac Effects of Padsevonil in Healthy Study Participants	Phase 1
	Completed	`NCT05845645` - A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharamacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B	Phase 1
	Completed	`NCT04802746` - A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma	Phase 1
	Completed	`NCT04782388` - Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian Participants	Phase 1
	Recruiting	`NCT06312566` - A Study to Assess the Bioequivalence Between Brivaracetam Tablet and Dry Syrup in Healthy Japanese Male Study Participants	Phase 1
	Completed	`NCT05292131` - A Bioequivalence Study of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection Using an Autoinjector in Healthy Study Participants	Phase 1
	Terminated	`NCT04444466` - A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria Participants	Phase 1
	Completed	`NCT04705350` - A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy Participants	Phase 1
	Terminated	`NCT04255862` - A Study to Evaluate the Bioequivalence of Bimekizumab Given as 1x2mL or 2x1mL Subcutaneous Injection in Healthy Study Participants	Phase 1
	Completed	`NCT04867642` - A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease	Phase 1
	Completed	`NCT04828343` - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Rozanolixizumab Administered Subcutaneously Via Manual Push Versus Syringe Driver to Healthy Participants	Phase 1